Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (12020)	12/3/1997 3:01:00 PM
From: james	Read Replies (1) \| Respond to of 32384

Henry, thanks for clarifying my confusions about lly/lgnd finance. The questions are probably answered many times before, & links are appreciated: <<The lion's share of these milestones are tied to starting a US diabetes trial for Targretin and IND filing for the two other rexinoids.>> Targretin is a pretty sure thing. Do you see any fallout from Glaxo's withdraw (though self-motivated). Are the other two also for type II as backups for Targretin, or for something else? <<an IND for LGD1268 is slated for 1Q,'98 as is the start of the US diabetes trial.>> Is LGD1268 not included in other deals mentioned before? Or is LGND doing it itself? <<LGND also can select one LLY drug (which I think is SRGN's fusion protein diptheria toxin coupled with IL-2) which will generate something like 80% margins.>>. The margins are great, but how about the market size? Thanks again I originally thought LGND would drop to $11+ months ago, but its holding at $13 has been strong. Sorry for the ignorance regards